CHEMOCENTRYX, INC.
Patent Owner
Stats
- 109 US PATENTS IN FORCE
- 4 US APPLICATIONS PENDING
- Mar 15, 2018 most recent publication
Details
- 109 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 2,493 Total Citation Count
- Aug 25, 2000 Earliest Filing
- 50 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2018/0029,986 POLYMORPHIC FORMS OF THE SODIUM SALT OF 4-TERT- BUTYL -N-[4-CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-BENZENE SULFONAMIDESep 29, 17Feb 01, 18[A61K, C07D]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2017/0327,508 DEUTERATED HETEROARYL SULFONAMIDES AND THEIR USEAbandonedMay 16, 17Nov 16, 17[C07D, C07B]
2011/0165,164 COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORSAbandonedDec 09, 10Jul 07, 11[A61K, C12Q, G01N, A61P]
2011/0052,589 COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORSAbandonedJun 11, 10Mar 03, 11[A61K, G01N, A61P]
2010/0278,820 REAGENTS THAT BIND CCX-CKR2AbandonedJan 21, 10Nov 04, 10[A61K, C07H, C12P, G01N, A61P, C07K]
2010/0247,540 Methods and Compositions For Modulating AngiogenesisAbandonedJul 20, 09Sep 30, 10[A61K, A61P]
2010/0144,720 INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2AbandonedDec 11, 09Jun 10, 10[A61K, C07D, C12N, C07C, A61P]
2010/0113,472 COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERSAbandonedNov 03, 09May 06, 10[A61K, A61P]
2009/0252,779 AZAINDAZOLE COMPOUNDS AND METHODS OF USEAbandonedApr 03, 09Oct 08, 09[A61K, A61F, C07D]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.
